Suzhou jingyun pharmaceutical technology co., ltd.

In the past, members of Jingyun's core team were directly responsible for and engaged in drug crystal research, crystallization process development and optimization in the world's leading pharmaceutical companies such as Merck, Bristol-Myers Squibb and Roche. * * * He has accumulated more than 60 years of R&D and management experience in this field, and has been responsible for and managed more than 200 crystal forms of drug molecules, held more than 40 patents on drug crystal forms, and published more than 65,438+000 papers in various international academic journals. R&D team members have rich experience in crystal research and strong technical force, among which overseas doctors account for about 30%, masters account for about 50% and bachelors account for about 20%.

The team developed the first high-tech platform in the field of drug crystal research and drug solid-state research and development by using the core technology mastered, and provided advanced technology research and development services in this field for global pharmaceutical enterprises through this platform. The company has high-tech and high-tech instruments with independent intellectual property rights, which not only ensures that the technology platform fills the gap in this field in China, but also makes it in the leading position in the world.

With rich experience and high-quality and efficient professional services, Jingyun team has established cooperative relations with more than 50 pharmaceutical companies around the world since the establishment of 20 10, and has become its close partners in the field of drug crystal research and drug solid-state research and development. With the continuous development of Jingyun, Jingyun will, as always, uphold the service concept of customer first and strive to provide more and more customers with advanced technical services that are always ahead of the forefront of science and technology.